A radioactive implant developed at Duke University eliminated tumors in the majority of mice tested with pancreatic cancer, producing what the research team calls the most effective results they have found across more than 1,100 pre-clinical treatments in the published literature. The findings were published in the journal Nature Biomedical Engineering.
At a glance
- Radioactive implant: The device uses a biocompatible gel to deliver iodine-131 directly into tumors, emitting beta radiation from within while preventing radioactive material from leaking into the body.
- Pancreatic cancer treatment: Across all mouse models tested, researchers recorded a 100% response rate; in three-quarters of the models, the dual treatment fully eliminated tumors 80% of the time.
- Pre-clinical results: After reviewing more than 1,100 treatments in existing pre-clinical literature, the team says they found no comparable cases where tumors shrank away and disappeared as completely as in their models.
Why pancreatic cancer is so hard to beat
Pancreatic cancer accounts for just 3.2% of all cancers, yet it is the third leading cause of cancer-related death. Its cells are highly evasive and carry mutations that make them resistant to many drugs, and tumors are often caught late.
One existing approach combines chemotherapy — which holds tumor cells in a vulnerable state — with targeted external radiation beams. But calibrating that treatment is difficult. Getting enough radiation into the tumor without exposing the surrounding body to heavy doses is a narrow margin, and the risk of severe side effects is real.
Implants placed directly inside the tumor offer a different path. Scientists have explored titanium shells encasing radioactive material, but those can damage the tissue around the tumor. “There’s just no good way to treat pancreatic cancer right now,” said study author Jeff Schaal.
How the implant works
Schaal and his colleagues turned to a class of synthetic amino acid chains called elastin-like polypeptides (ELPs). These materials remain liquid at room temperature but form a stable gel when they encounter the warmer environment inside the body — a property that makes them practical to inject and reliable once placed.
The team mixed ELPs with iodine-131, a radioactive isotope that is already well-studied and widely used in medical treatment. Injected directly into a tumor, the ELP solidifies and traps the iodine-131 in place, preventing it from leaking into surrounding tissue. At the same time, the gel allows beta radiation to pass through and penetrate the tumor from the inside out. Once the radioactive material is spent, the ELP biogel breaks down into harmless amino acids and is safely cleared by the body.
The implant was used alongside paclitaxel, a common chemotherapy drug. The combination was tested in mouse models where tumors were grown just beneath the skin — with mutations characteristic of pancreatic cancer — and in tumors grown within the pancreas itself, which are historically harder to treat.
Results the team calls unparalleled
Across every model tested, the treatment produced a 100% response rate. In three-quarters of the models, the combined approach completely eliminated tumors 80% of the time. Those numbers stood out even more after the team surveyed the broader scientific record.
“We did a deep dive through over 1,100 treatments across preclinical models and never found results where the tumors shrank away and disappeared like ours did,” Schaal said. “When the rest of the literature is saying that what we’re seeing doesn’t happen, that’s when we knew we had something extremely interesting.”
Team member Ashutosh Chilkoti described these as “perhaps the most exciting” results against late-stage pancreatic cancer his lab has produced in nearly 20 years.
The researchers also believe the approach may extend well beyond pancreatic cancer. Because the implant delivers constant low-level radiation rather than intermittent external beams, it may allow chemotherapy drugs to interact more powerfully with the radiation’s effects. “We think the constant radiation allows the drugs to interact with its effects more strongly than external beam therapy allows,” Schaal said. “That makes us think that this approach might actually work better than external beam therapy for many other cancers, too.”
What comes next — and what remains unproven
These results, striking as they are, come entirely from mouse models. The immediate next step is trials on larger animals, and the distance between a promising pre-clinical result and an approved human treatment is long. Many cancer therapies that show dramatic results in rodents do not replicate those outcomes in human trials, and the ELP-iodine-131 system has yet to be tested for safety or efficacy in any human subject.
Still, the team’s exhaustive review of existing literature — and the consistency of the results across multiple tumor models — gives the findings unusual weight even at this early stage. The study was published in Nature Biomedical Engineering, one of the field’s most rigorous peer-reviewed journals.
Pancreatic cancer’s resistance to treatment has made it a benchmark for difficulty in oncology. A delivery system that performs this well against it, and that the body can safely absorb after the fact, would represent a meaningful shift in what’s possible — if the results hold as the research moves toward human trials.
For a disease where survival rates have improved only modestly over decades, the Duke University team’s work on this front offers a rare and genuinely encouraging early signal.
Read more
For more on this story, see: New Atlas — Radioactive implant wipes tumors in unprecedented pre-clinical success
For more from Good News for Humankind, see:
- Renewables now make up at least 49% of global power capacity
- U.K. cancer death rates down to their lowest level on record
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
